Serlopitant shows promise for psoriatic pruritus in phase 2 trial

  • Pariser DM & al.
  • J Am Acad Dermatol
  • 30/01/2020

  • Brian Richardson, PhD
  • Clinical Essentials
L'accesso ai contenuti di questo sito è riservato agli operatori del settore sanitario italiano L'accesso ai contenuti di questo sito è riservato agli operatori del settore sanitario italiano

Takeaway

  • Serlopitant, a neurokinin 1 receptor antagonist, is associated with improved itch symptoms in patients with psoriatic pruritus, according to a phase 2 clinical trial.

Why this matters

  • Many available treatment options for psoriasis do not adequately address pruritus.

Key results

  • Vs placebo, serlopitant was associated with a higher worst itch numeric rating scale (WI-NRS) response rate at:
    • 4 weeks: 20.8% vs 11.5% (P=.039). 
    • 8 weeks: 33.3% vs 21.1% (P=.028).
  • 4.9% of patients who received serlopitant and 4.0% of patients who received placebo experienced treatment-related adverse events.

Study design

  • 204 patients with psoriatic pruritus were randomly assigned to serlopitant 5 mg or placebo daily for 8 weeks.
  • Funding: Menlo Therapeutics, Inc.

Limitations

  • Relatively small patient sample size.
  • Short trial duration.
  • Patients with severe psoriasis were excluded.